Pfizer delivered a strong Q2 2025, beating revenue and EPS estimates, raising EPS guidance, and maintaining its attractive dividend yield above 7%. Product portfolio strength is evident, with growth ...
In the latest quarter, 7 analysts provided ratings for Pfizer (NYSE:PFE), showcasing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, ...
GLP-1 drugs have seen strong consumer demand. Eli Lilly's industry-leading GLP-1 drugs Mounjaro and Zepbound, for example, saw revenue growth of 99% and 175%, respectively, in 2025. The flameout of ...
Regulatory Recon is our daily intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. A story’s inclusion in ...
Pfizer's declining revenue and questions about its growth have weighed down the stock in recent years. The company, however, has been bolstering its pipeline and has some exciting assets. Its ...
A second candidate vaccine against COVID-19 is undergoing rolling review by the European Medicines Agency (EMA), as the agency begins with evaluation of pre-clinical data to support approval of a ...
Pfizer obtains priority review for talazoparib in treating patients with germline BRCA-mutated breast cancer, with FDA decision date by December 2018. Treatment with talazoparib in BRCA-mutated breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results